–Strong anti-tumor activity, favorable oral bioavailability and drug-like properties demonstrated in preclinical models – –Data support ongoing IND-enabling studies for planned clinical evaluation in KRASG12V-driven solid tumors – RADNOR, Pa. & SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company leading innovative development of direct, oral therapeutics for RAS-driven cancers, announced the presentation of QTX3544, a multi-KRAS inhibitor with G12V-preferring activity (G12V+ multi-KRAS), in a late-breaking poster presentation session at the American Association of Cancer Research (AACR) Annual Meeting.

–在临床前模型中证明了强大的抗肿瘤活性，良好的口服生物利用度和类似药物的特性–数据支持正在进行的IND支持研究，用于KRASG12V驱动的实体瘤的计划临床评估–宾夕法尼亚州拉德诺和加利福尼亚州南旧金山，2024年4月8日（环球通讯社）-Quanta Therapeutics是一家私营生物制药公司，领先于RAS驱动的癌症直接口服治疗剂的创新开发，在美国癌症研究协会（AACR）年会的最新海报展示会上宣布了QTX3544，一种具有G12V偏好活性的多KRAS抑制剂（G12V+多KRAS）。

QTX3544 demonstrated a favorable preclinical profile, including high selectivity and potent activity against multiple KRAS mutations with preference for the G12V mutation. Additionally, QTX3544 significantly inhibited KRASG12V tumor growth in preclinical animal models and exhibited promising oral bioavailability and pharmacokinetic properties.

QTX3544表现出良好的临床前特征，包括对多个KRAS突变的高选择性和有效活性，优先于G12V突变。此外，QTX3544在临床前动物模型中显着抑制KRASG12V肿瘤生长，并表现出有希望的口服生物利用度和药代动力学特性。

“We continue to advance our pipeline of candidates against KRAS-driven cancer mutations focusing on the most prevalent drivers, G12D and G12V,” said Perry Nisen, MD, PhD, Chief Executive Officer of Quanta. “Along with our two lead G12D-focused programs in or near the clinical stage, we are very excited about this third program, which will focus initially on the approximately 20% of KRAS-driven cancers with the G12V mutation.

Quanta首席执行官Perry Nisen博士说：“我们继续推进针对KRAS驱动的癌症突变的候选人渠道，重点关注最普遍的驱动因素G12D和G12V。”。“除了我们在临床阶段或临床阶段附近的两个主要G12D重点项目外，我们对第三个项目感到非常兴奋，该项目最初将重点关注大约20%的具有G12V突变的KRAS驱动的癌症。

We look forward to completing IND-enabling studies for QTX3544 this year to support future clinical studies in patients with G12V-mutated solid tumors, a population without targeted treatment options.” Data from the presentation are summarized below. Data for QTX3544 demonstrated: High biochemical potency against multiple KRAS variants.

我们期待着今年完成QTX3544的IND支持研究，以支持G12V突变实体瘤患者的未来临床研究，这些患者没有针对性的治疗选择。”演示文稿中的数据总结如下。QTX3544的数据表明：对多种KRAS变体具有高生化效力。